<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40716702</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-2030</ISSN><JournalIssue CitedMedium="Internet"><Volume>156</Volume><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Contemporary clinical trials</Title><ISOAbbreviation>Contemp Clin Trials</ISOAbbreviation></Journal><ArticleTitle>Association of study visit interval length with follow-up completeness and adherence to assigned study drug dose: A randomized comparison of participants in the ADAPTABLE trial.</ArticleTitle><Pagination><StartPage>108030</StartPage><MedlinePgn>108030</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cct.2025.108030</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1551-7144(25)00224-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Little is known of the frequency of follow-up visits impact on completion of scheduled study visits, adherence to randomized treatment assignment, and completion of the study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In ADAPTABLE, participants with ASCVD were randomized to 81&#xa0;mg or 325&#xa0;mg of aspirin and to follow-up at 3- or 6-month intervals. At follow-up, participants answered questions about aspirin dose, adherence, and outcome measures via internet patient portal or telephone. Differences in visit adherence and study completion were compared using logistic regression. Proportional hazard models were used to compare time to study drop out, stopping aspirin, or changing aspirin dose between the 3-and 6-month groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">When compared with 6-month follow-up, participants assigned to 3-month follow-up were less likely to attend any study visit (OR 0.69, 95&#xa0;% CI 0.65-0.73), but 3-month follow-up had more total visits (8 vs 5, p&#xa0;&lt;&#xa0;0.0001). The likelihood of completing the end-of-study visit were similar (OR 0.94, 95&#xa0;% CI 0.87-1.03). Assignment to 3- vs 6-month follow-up was not associated with rates of aspirin dose switching (HR 1.02, 95&#xa0;% CI&#xa0;=&#xa0;0.94-1.09), aspirin discontinuation (HR 1.00, 95&#xa0;% CI 0.88-1.14), or study drop out (HR 0.95, 95&#xa0;% CI 0.88-1.03).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">More frequent study visits led to higher total visits but lower visit adherence. There were no significant differences in visit and medication adherence between 3 v. 6&#xa0;months follow up. As we continue to refine approaches to designing pragmatic clinical trials, more work is needed to understand the factors that may impact adherence to randomized assignments.</AbstractText><AbstractText Label="CLINICALTRIALS" NlmCategory="RESULTS">govIdentifier:NCT02697916.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Narcisse</LastName><ForeName>Dennis I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University, Durham, NC, United States of America. Electronic address: dennis.narcisse@duke.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whittle</LastName><ForeName>Jeff</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clement J. Zablocki VA Medical Center, Milwaukee, WI, United States of America; Medical College of Wisconsin, Milwaukee, WI, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhodes</LastName><ForeName>Grace M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stebbins</LastName><ForeName>Amanda L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wruck</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulder</LastName><ForeName>Hillary</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kripalani</LastName><ForeName>Sunil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Vanderbilt University Medical Center, Nashville, TN, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu&#xf1;oz</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Vanderbilt University Medical Center, Nashville, TN, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Effron</LastName><ForeName>Mark B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Ochsner Health, New Orleans, LA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Kamal</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University of Kansas Medical Center, Kansas City, KS, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Handberg</LastName><ForeName>Eileen M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>University of Florida, Gainesville, FL, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girotra</LastName><ForeName>Saket</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Texas Southwestern, Dallas, TX, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hess</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benziger</LastName><ForeName>Catherine P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Essentia Health Heart and Vascular Center, Duluth, MN, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrehi</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University of Michigan, Ann Arbor, MI, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>VanWormer</LastName><ForeName>Jeffrey J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Marshfield Clinic Research Institute, Marshfield, WI, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knowlton</LastName><ForeName>Kirk U</ForeName><Initials>KU</Initials><AffiliationInfo><Affiliation>Intermountain Medical Center Heart Institute, Salt Lake City, UT, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polonsky</LastName><ForeName>Tamar S</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>University of Chicago Medicine, Chicago, IL, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradley</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Allina Health Minneapolis Heart Institute, Minneapolis, MN, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robertson</LastName><ForeName>Holly R</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammill</LastName><ForeName>Bradley G</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothman</LastName><ForeName>Russell L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Vanderbilt University Medical Center, Nashville, TN, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrington</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Weill Cornell Medicine and New York-Presbyterian Hospital, New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>W Schuyler</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Adrian F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University, Durham, NC, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02697916</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Contemp Clin Trials</MedlineTA><NlmUniqueID>101242342</NlmUniqueID><ISSNLinking>1551-7144</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>R16CO5Y76E</RegistryNumber><NameOfSubstance UI="D001241">Aspirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001241" MajorTopicYN="Y">Aspirin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010975" MajorTopicYN="Y">Platelet Aggregation Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001071" MajorTopicYN="Y">Appointments and Schedules</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055118" MajorTopicYN="N">Medication Adherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009819" MajorTopicYN="Y">Office Visits</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular disease</Keyword><Keyword MajorTopicYN="N">Clinical trials</Keyword><Keyword MajorTopicYN="N">Coronary artery disease</Keyword><Keyword MajorTopicYN="N">Pragmatic clinical trials</Keyword><Keyword MajorTopicYN="N">Prevention</Keyword></KeywordList><CoiStatement>Declaration of competing interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>8</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>29</Day><Hour>4</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>19</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40716702</ArticleId><ArticleId IdType="doi">10.1016/j.cct.2025.108030</ArticleId><ArticleId IdType="pii">S1551-7144(25)00224-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>